Securities Claims In Drug Company Merger Deal Class Action Not Plausibly Pleaded
PHILADELPHIA — A federal district court did not err in dismissing shareholder claims alleging that a commercial-stage biopharmaceutical company and its board of directors violated federal securities law by failing to...To view the full article, register now.
Already a subscriber? Click here to view full article